RBD Ligand Biomarker Selection for Pancreatic Cancer Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing pancreatic cancer lack specific biomarkers, particularly metabolic biomarkers, making it difficult to accurately detect pancreatic cancer at early stages, which is crucial for effective therapeutic strategies.
Innovation Solution
Development of receptor-binding domain (RBD) ligands derived from the soluble part of glycoproteins of enveloped viruses, specifically targeting cell surface nutrient transporters like ASCT1, ASCT2, and XPR1, for use in medical imaging and diagnostic methods such as MRI, CT, and PET scans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional medical imaging techniques (CT, MRI, PET) are used for pancreatic cancer detection, then general imaging capability is provided, but specific detection of pancreatic cancer cells is insufficient due to lack of reliable biomarkers
Solution Approach 1:
The invention changes the biomarker parameter from conventional markers like GLUT1 to ASCT2, which demonstrates significantly higher and more consistent overexpression in pancreatic cancer cells. This parameter change enables more reliable and specific detection of pancreatic cancer through imaging techniques.
2Measurement precision
If GLUT1 is used as a biomarker for PET imaging, then glucose metabolism detection is enabled, but detection accuracy for pancreatic cancer is insufficient due to unreliable GLUT1 overexpression
Solution Approach 1:
The invention transitions from using GLUT1 as the biomarker parameter to ASCT2, which shows more consistent and higher overexpression levels in pancreatic cancer. This parameter change improves detection accuracy while maintaining versatility across different pancreatic cancer cell lines and types.
3Measurement precision
If no specific biomarker is available for pancreatic cancer, then general imaging methods can be applied, but accurate and definitive detection at early stages is not achieved
Solution Approach 1:
The invention identifies and utilizes ASCT2 as a new biomarker parameter that is overexpressed in pancreatic cancer cells. This discovery provides the necessary biomarker quantity and quality to enable accurate early-stage detection through imaging techniques.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to methods for diagnosing pancreatic cancer, wherein said methods comprises measuring the expression level of ASCT1 and/or ASCT2 and/or XPR1. The present invention further relates to a RBD ligand coupled to at least one contrast agent, that may be used as a probe for medical imaging.